SCHEMBL3887478

SCHEMBL3887478

Cc1cccc(-c2cc3ccccn3c2C(=O)C(=O)Cl)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.56
THRB P10828 1/20 0.53
L3MBTL1 Q9Y468 6/20 0.50
MAPT P10636 7/20 0.47
HTT P42858 4/20 0.47
TRPV1 Q8NER1 1/20 0.44
ALDH1A1 P00352 6/20 0.43
LMNA P02545 3/20 0.43
CYP1A2 P05177 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
ATM Q13315 1/20 0.42
KMT2A Q03164 4/20 0.41
KDM4E B2RXH2 3/20 0.41
MEN1 O00255 3/20 0.41
POLB P06746 1/20 0.41
RAB9A P51151 3/20 0.40
TDP1 Q9NUW8 2/20 0.40
RECQL P46063 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3886744 0.87 SMN1; SMN2 (0.59) SMN1; SMN2THRBL3MBTL1MAPTHTT
SCHEMBL1645731 0.86 SMN1; SMN2 (0.68) SMN1; SMN2THRBL3MBTL1MAPTHTT
SCHEMBL3885387 0.86 SMN1; SMN2 (0.54) SMN1; SMN2THRBL3MBTL1MAPTHTT
SCHEMBL3885802 0.85 SMN1; SMN2 (0.53) SMN1; SMN2THRBL3MBTL1MAPTHTT
SCHEMBL3892020 0.82 SMN1; SMN2 (0.51) SMN1; SMN2THRBL3MBTL1MAPTHTT
SCHEMBL3887651 0.82 SMN1; SMN2 (0.52) SMN1; SMN2THRBL3MBTL1MAPTHTT
SCHEMBL3886862 0.80 SMN1; SMN2 (0.50) SMN1; SMN2THRBL3MBTL1MAPTHTT
SCHEMBL3886464 0.80 SMN1; SMN2 (0.56) SMN1; SMN2THRBL3MBTL1MAPTHTT
SCHEMBL1646584 0.79 SMN1; SMN2 (0.55) SMN1; SMN2THRBL3MBTL1MAPTHTT
SCHEMBL3897320 0.79 SMN1; SMN2 (0.55) SMN1; SMN2THRBL3MBTL1MAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8486962-B2 N-(2-Methoxy-phenyl)-2-oxo-2-(2-phenyl-indolizin-3-yl)-acetamide; antifungal agents; inhibiting Aspergillus F2G LTD. (GB) 2013-07-16 US disclosed
EP-1888063-B1 ANTIFUNGAL AGENTS F2G LTD (GB) 2009-01-14 EP disclosed
US-20080161302-A1 N-(2-Methoxy-phenyl)-2-oxo-2-(2-phenyl-indolizin-3-yl)-acetamide; antifungal agents; inhibiting Aspergillus F2G LTD. (GB) 2008-07-03 US disclosed
EP-1888063-A1 ANTIFUNGAL AGENTS F2G Ltd. (GB) 2008-02-20 EP disclosed
WO-2006123145-A1 ANTIFUNGAL AGENTS F2G LTD (GB) 2006-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080161302-A1 N-(2-Methoxy-phenyl)-2-oxo-2-(2-phenyl-indolizin-3-yl)-acetamide; antifungal agents; inhibiting Aspergillus NAT1, CYP1A2, CYP51A1 SMN1; SMN2 3501/4885THRB 2955/4885L3MBTL1 3386/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.